Trehalose and aortic inflammation

Investigation of the therapeutic effects of Trehalose in aortic inflammation in patients with cancer

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130829014521N20

Enrollment

Registered

2022-06-07

Start date

2022-06-22

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic inflammation in patients with cancer. Arteritis, unspecified

Interventions

Intervention group: one dose of Trehalose by intravenous injection (15 gr/ml).

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cancer patients with aortic inflammation with a cutoff of 1.6 or more for the TBR in the first scan

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Investigation of aortic inflammation with (18F-FDG PET) scan. Timepoint: one week after administration of trehalose. Method of measurement: (18F-FDG PET) scan.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contact?Amirhossein Sahebkar

Mashhad University of Medical Sciences

sahebkara@mums.ac.ir+98 51 1882 9260

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026